ArticlePharmaceutical research2009
Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.
Article in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 132 citations in OpenAlex.
- Polymeric and lipidic nanoparticles in transforming anti-HIV combinational therapy: can they turn the tide?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Functional role and regulation of permeability-glycoprotein (P-gp) in the fetal membrane during drug transportation.American journal of reproductive immunology (New York, N.Y. : 1989) · 2022Article
- Recent Advances in the Excipients Used in Modified Release Vaginal Formulations.Materials (Basel, Switzerland) · 2022Review
- In vitro dissolution considerations associated with nano drug delivery systems.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.Pharmacology research & perspectives · 2021Review
- The Prospect of Nanoparticle Systems for Modulating Immune Cell Polarization During Central Nervous System Infection.Frontiers in immunology · 2021Article
- The Potential of Atractylodin-Loaded PLGA Nanoparticles as Chemotherapeutic for Cholangiocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Design of Poly(lactic-Pharmaceutics · 2019Article
- Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.Pharmaceutical research · 2019Article
- Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems.Pharmaceutics · 2019Review
- Pharmaceutical Approaches to HIV Treatment and Prevention.Advanced therapeutics · 2018Article
- Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide.International journal of nanomedicine · 2018Article
- On-demand microbicide products: design matters.Drug delivery and translational research · 2017Review
- "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.Drug delivery · 2017Review
- Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV prevention.Journal of pharmaceutical innovation · 2017Article
- Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Review
- Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.Journal of nanotechnology and materials science · 2017Article
- Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.Antimicrobial agents and chemotherapy · 2016Article
- Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities.Therapeutic delivery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeNanoparticles formulated from the biodegradable co-polymer poly(lactic-co-glycolic acid) (PLGA), were investigated as a drug delivery system to enhance tissue uptake, permeation, and targeting for PSC-RANTES anti-HIV-1 activity. MATERIALS AND
methodsPSC-RANTES nanoparticles formulated via a double emulsion process and characterized in both in vitro and ex vivo systems to determine PSC-RANTES release rate, nanoparticle tissue permeation, and anti-HIV bioactivity.
resultsSpherical, monodisperse (PDI = 0.098 +/- 0.054) PSC-RANTES nanoparticles (d = 256.58 +/- 19.57 nm) with an encapsulation efficiency of 82.23 +/- 8.35% were manufactured. In vitro release studies demonstrated a controlled release profile of PSC-RANTES (71.48 +/- 5.25% release). PSC-RANTES nanoparticle maintained comparable anti-HIV activity with unformulated PSC-RANTES in a HeLa cell-based system with an IC(50) of approximately 1pM. In an ex vivo cervical tissue model, PSC-RANTES nanoparticles displayed a fivefold increase in tissue uptake, enhanced tissue permeation, and significant localization at the basal layers of the epithelium over unformulated PSC-RANTES.
conclusionsThese results indicate that PSC-RANTES can readily be encapsulated into a PLGA nanoparticle drug delivery system, retain its anti-HIV-1 activity, and deliver PSC-RANTES to the target tissue. This is crucial for the success of this drug candidate as a topical microbicide product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.